Placebo capsules - end of infusion

DRUG2 trials

Sponsors

The Medicines Company

Conditions

Acute Coronary Syndrome (ACS)Acute Coronary Syndromes (ACS)AtherosclerosisMyocardial Infarction (MI)

Phase 3

A Clinical Trial to Demonstrate the Efficacy of Cangrelor

TerminatedNCT00305162

The Medicines CompanyAcute Coronary Syndromes (ACS), Myocardial Infarction (MI)

Start: 2006-04-30End: 2010-06-30Updated: 2014-05-08

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

TerminatedNCT00385138

The Medicines CompanyAcute Coronary Syndrome (ACS), Atherosclerosis

Start: 2006-09-30End: 2010-06-30Updated: 2014-05-05

Related Papers

Effect of Platelet Inhibition by Cangrelor Among Obese Patients Undergoing Coronary Stenting: Insights From CHAMPION

Circulation Cardiovascular Interventions2022-02-241 citations

Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention – Insights from the CHAMPION program

American Heart Journal Plus Cardiology Research and Practice2021-08-25

Incidence, Predictors, and Outcomes of Acquired Thrombocytopenia After Percutaneous Coronary Intervention

Circulation Cardiovascular Interventions2018-04-0120 citations

Cangrelor With and Without Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention.

2017-01-0142 citations

Evaluation of Ischemic and Bleeding Risks Associated With 2 Parenteral Antiplatelet Strategies Comparing Cangrelor With Glycoprotein IIb/IIIa Inhibitors

JAMA Cardiology2016-11-3050 citations

Intravenous platelet blockade with cangrelor during PCI.

2009-12-01435 citations

Platelet inhibition with cangrelor in patients undergoing PCI.

2009-12-01401 citations